Skip to main content

Rigel Pharmaceuticals, Inc. (RIGL)

NASDAQ: RIGL · Delayed Price · USD
3.45
+0.17 (5.18%)
Pre-market:Oct 22, 2021 4:45 AM EDT
3.28
-0.05 (-1.50%)
At close: Oct 21, 4:00 PM
Market Cap566.35M
Revenue (ttm)144.12M
Net Income (ttm)-7.73M
Shares Out170.19M
EPS (ttm)-0.05
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume635,489
Open3.33
Previous Close3.33
Day's Range3.27 - 3.37
52-Week Range2.36 - 5.50
Beta1.54
AnalystsBuy
Price Target8.33 (+154.0%)
Est. Earnings DateNov 4, 2021

About RIGL

Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase II clinical trial for the treatment of hospitalized COVID-19 patients; and phase II clinical trial for the treatme...

IndustryBiotechnology
IPO DateNov 29, 2000
CEORaul Rodriguez
Employees169
Stock ExchangeNASDAQ
Ticker SymbolRIGL
Full Company Profile

Financial Performance

In 2020, RIGL's revenue was $108.62 million, an increase of 83.21% compared to the previous year's $59.29 million. Losses were -$29.74 million, -55.54% less than in 2019.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for RIGL stock is "Buy." The 12-month stock price forecast is 8.33, which is an increase of 153.96% from the latest price.

Price Target
$8.33
(153.96% upside)
Analyst Consensus: Buy

News

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Oct. 8, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported the grant of stock options to purchase an aggregate of 469,000 shares of common stock ...

1 week ago - PRNewsWire

Rigel to Participate in Three Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 2, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, and Dean S...

1 month ago - PRNewsWire

Data from NIH/NHLBI-Sponsored Phase 2 Trial of Fostamatinib in Hospitalized COVID-19 Patients Published in Clinical I...

SOUTH SAN FRANCISCO, Calif., Sept. 1, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced the publication of results from a Phase 2 clinical trial evaluating the safety of f...

1 month ago - PRNewsWire

Why Did the FDA Reject Rigel's EUA Application for Its COVID-19 Therapy?

More data is needed.

1 month ago - The Motley Fool

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rigel Pharmaceuticals, Inc. - RIGL

New York, New York--(Newsfile Corp. - August 17, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Rigel Pharmaceuticals, Inc. ("Rigel" or the "Company") (NASDAQ: RIGL). Such inves...

2 months ago - Newsfile Corp

Rigel (RIGL) COVID-19 Treatment Denied By FDA for EUA

Rigel Pharmaceuticals' (RIGL) fostamatinib does not get the FDA's nod for emergency use for COVID-19. The company plans to submit data from a larger study.

2 months ago - Zacks Investment Research

Rigel Stock Falls After Update From COVID-19 Program

The FDA has informed Rigel Pharmaceuticals Inc (NASDAQ: RIGL) that data submitted in May from fostamatinib Phase 2 trial for COVID-19 is insufficient for an emergency use authorization (EUA). Rigel subm...

2 months ago - Benzinga

Rigel Pharmaceuticals Provides Update on COVID-19 Program

SOUTH SAN FRANCISCO, Calif., Aug. 13, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that clin...

2 months ago - PRNewsWire

Implied Volatility Surging for Rigel Pharmaceuticals (RIGL) Stock Options

Investors need to pay close attention to Rigel Pharmaceuticals (RIGL) stock based on the movements in the options market lately.

2 months ago - Zacks Investment Research

Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue Estimates

Rigel (RIGL) delivered earnings and revenue surprises of 27.27% and 18.96%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Rigel Reports Second Quarter 2021 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., Aug. 3, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the second quarter ended June 30, 2021, including sales of TAVAL...

2 months ago - PRNewsWire

Earnings Preview: Rigel Pharmaceuticals (RIGL) Q2 Earnings Expected to Decline

Rigel (RIGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Rigel Announces Conference Call and Webcast to Report Second Quarter 2021 Financial Results and Business Update

SOUTH SAN FRANCISCO, Calif., July 27, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its second quarter 2021 financial results after market close on T...

2 months ago - PRNewsWire

3 Biotech Stocks That Could Rocket Higher

Over the past year, these small-cap drugmakers have done well by their shareholders, and more big catalysts could be coming.

Other symbols:BCRXLLY
2 months ago - The Motley Fool

New TAVALISSE® Data Analyses To Be Presented at International Society on Thrombosis and Haemostasis (ISTH) 2021 Congress

SOUTH SAN FRANCISCO, Calif., July 14, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that data from its clinical development program for TAVALISSE® (fostamatinib disodi...

3 months ago - PRNewsWire

Top Biotech Penny Stocks to Buy This Week? 9 To Watch

Biotech penny stocks continue to climb, which companies are on your watchlist? The post Top Biotech Penny Stocks to Buy This Week?

Other symbols:ADXSEYESSNES
3 months ago - PennyStocks

Fostamatinib Selected for NIH ACTIV-4 COVID-19 Clinical Trial

SOUTH SAN FRANCISCO, Calif., June 29, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that fostamatinib, the Company's novel oral spleen tyrosine kinase (SYK) inhibitor,...

3 months ago - PRNewsWire

Top Penny Stocks to Buy in July? 7 You May Not Know About

Looking for penny stocks to buy in July 2021? Here's 7 for your watchlist The post Top Penny Stocks to Buy in July?

Other symbols:AIHSASXCBESTCYRNITRM
3 months ago - PennyStocks

Rigel to Present at the Jefferies Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 26, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is schedule...

4 months ago - PRNewsWire

Rigel Appoints Alison L. Hannah, M.D.

SOUTH SAN FRANCISCO, Calif., May 14, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has appointed Alison L.

5 months ago - PRNewsWire

Rigel Pharmaceuticals (RIGL) Tops Q1 Earnings and Revenue Estimates

Rigel (RIGL) delivered earnings and revenue surprises of 2100.00% and 102.24%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Rigel Reports First Quarter 2021 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., May 5, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the first quarter ended March 31, 2021, including sales of TAVALI...

5 months ago - PRNewsWire

Rigel Announces Conference Call and Webcast to Report First Quarter 2021 Financial Results and Business Update

SOUTH SAN FRANCISCO, Calif., April 28, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its first quarter 2021 financial results after market close on W...

5 months ago - PRNewsWire

Why Rigel Pharmaceuticals Stock Jumped Today

The company announced positive results from an important COVID-19 clinical study.

6 months ago - The Motley Fool

Positive Topline Data Shows Fostamatinib Meets Primary Endpoint of Safety in Phase 2 Clinical Trial in Hospitalized P...

SOUTH SAN FRANCISCO, Calif., April 13, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced positive topline results from a multi-center, Phase 2 clinical trial to evaluate t...

6 months ago - PRNewsWire